NT Radiation Oncology and the Oncology departments at the Royal Darwin Hospital jointly conducts research and clinical trials to find more effective ways to prevent, treat, cure and support those living with cancer. Our clinical trials also provide the opportunities for our patients to access leading edge treatment and care protocols.
Alan Walker Cancer Care Centre promotes integrity in its research and clinical trials as it operates in accordance with the National Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research (2007).
Menzies School of Health Research – National Support Needs Study
A study to assess the support care needs of Aboriginal and Torres Strait Islander cancer patients. This is an important study because Indigenous patients have more difficulty in accessing services and may have higher unmet needs in relation to their cancer diagnosis/treatment.
TROG – Palliative Lung
A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy + HDRPT (C-HDRPT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy
TROG – ‘STARS’ – Breast Cancer
A randomised comparison of Anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy
AGITG – ‘SCOT’ – Colorectal – Patients in follow up
Short course oncology therapy – a study of adjuvant chemotherapy in colorectal cancer
Roche/Quintiles – ‘CoBRIM’ – Metastatic melanoma– Patients in follow up
A phase III, double-blind, placebo-controlled study of Vemurafenib + placebo versus Vemurafenib in combination with GDC-0973 in previously untreated BRAF-mutation positive patients with unresectable locally advanced or metastatic melanoma
TROG – WBRTMel – Whole brain radiation for metastatic melanoma
Whole brain radiotherapy following local treatment of intracranial metastases of melanoma
ANZUP – ‘Enzamet’ – New drug treatment for Prostate cancer
Randomised, phase III trial of enzalutimide in first line androgen deprivation therapy for metastatic prostate cancer
ALLG – NHL26 ‘RePLY’ – Relapsed follicular lymphoma
A phase II study of patients treated for relapsed follicular lymphoma: with Revlimid consolidation added to Rituximab maintenance therapy in those remaining PET positive